BCG immunotherapy showed a significant advantage over mitomycin C with regard to recurrence (hazard ratio 2.0). The results are impressive, even with such a long follow-up period and as few as 45 ...

Outcome of BCG immunotherapy of bladder cancer may ultimately depend on imbalance of Th1/Th17–Th2–regulatory T-cell axis. It is important to determine the expression and potential role of ...

Although the use of intravesical immunotherapy for reducing tumor progression ... 33 randomized two groups of patients with CIS to receive BCG and eMCC. One group was randomly assigned BCG 81 ...

This article summarizes the current understanding of BCG cancer immunotherapy mechanisms and discusses possible future developments. Financial & Competing Interests Disclosure: The authors have no ...

The BCG vaccine was first used against TB in the 1920's and then started to be used as the first cancer immunotherapy around ...

Bacillus Calmette-Guérin (BCG). The novel treatment, cretostimogene grenadenorepvec, is an oncolytic immunotherapy, meaning it is a virus designed to selectively replicate in and break down ...

Bacillus Calmette-Guérin (BCG). The novel treatment, cretostimogene grenadenorepvec, is an oncolytic immunotherapy, meaning it is a virus designed to selectively replicate in and break down ...